GNTA

Genenta Science
GNTA

$4

0.74%

Market Cap: $72.9M

About: Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

Employees: 14

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 4 [Q1] → 4 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

1.26% less ownership

Funds ownership: 2.61% [Q1] → 1.35% (-1.26%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

57% less capital invested

Capital invested by funds: $1.74M [Q1] → $756K (-$984K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GNTA.

See Analyst Rankings

Financial journalist opinion

7 Penny Biotech Stocks to Triple Your Investment

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.

7 Penny Biotech Stocks to Triple Your Investment

Genenta Welcomes New Directors John L. Cantello, Lauren H.

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

See News Rankings